The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
|Articles|May 17, 2022
Rheumatoid Arthritis Quiz: Interstitial Lung Disease
Author(s)Ingrid Torjesen
Many rheumatoid arthritis (RA) patients experience lung manifestations such as interstitial lung disease, but what are the implications and who is most at risk? Test your knowledge with this quiz.
Advertisement
Is the following statement true or false?
Interstitial lung disease (ILD) is the leading cause of premature death in rheumatoid arthritis?
Advertisement
Related to this article
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement